The 15th of March, Susana Marcos was invited by Saint Louis University to give a Ted Talk in the university´s campus of Madrid. The topic was "Better eyesight for improving quality of live". Check it out on the following video and learn more technologies to improve eye diagnostics, including SimVis
Carlos Dorronsoro, Susana Marcos and José Ramon Alonso, inventors of SimVis, receive best patent award
Carlos Dorronso, Susana Marcos and José Ramón Alonso, received on Monday 19th of March 2018 the Best Patent Prize by Fundación Madri+d. The patent awarded protects the SimVis technology and was highly valued by the jury for its quality and market impact.
You can obtain more information on the following links:
– XII Premios Madri+d .
– Telemadrid News.
– More information about the patent’s technology here.
NEOTEC is one of the most competitive financing calls in Spain. Every year hundreds of Spanish Small and Medium enterprises compete for this grants, a subsidy that covers up to 70% of a company´s business plan. The proposal presented by 2Eyes Vision has been valued very positively. 351 proposals were submitted and 92 awarded with a cut-off of 73.5 points and 2Eyes being the sixth best-rated proposal with a score of 86.5.
IMCUSTOMEYE is a european consortium lead by the VioBio Lab and formed by 2Eyes Vision, CSIC-VioBio Lab, University of Liverpool, National University of Ireland (Galway), Instytut Chemi Fizycznej Polskiej Akademii Nauk, Instituto Oftalmológico Fernández Vega, University College London, Iroc Science AG, Oculus Optikgerate GmbH and Optimo Medical AG. The goal of the project is to develop an OCT that takes tridimensional images of the eye to diagnose different ocular patologies such as glaucoma, keratoconus, cataracts, refractive errors, etc.
During the 2 day kick off event hosted by the VioBio Lab in Madrid, representatives of all consortium members presented their research activities and expected contributions to the project, and held 10 round table discussions on technical aspects of the project, IP handling, and commercialization, among others.
2Eyes Vision, specialist in the creation and development of ophthalmic technologies secures an investment from Bullnet Capital
· The company has developed SimVis, the first technology ever allowing presbyopic and cataract patients to experience the real world through multifocal corrections before intraocular lens implantation, refractive surgery, or contact lens fitting..
· The investment will allow the company to release a first version of the product and start its commercialization.
Madrid, 4th December 2017—2Eyes Vision, spin off of the Visual Optics and Biophotonics Laboratory of the Spanish National Research Council (CSIC) has announced today a Series A investment led by Bullnet Capital. The investment will provide the company with the necessary resources to strengthen product development and to create a sales and marketing structure.
The SimVis technology is the result of a 7 year investigation and it allows cataract and presbyopic patients to experience, for the first time, the real world through multifocal corrections before contact lens fitting and intraocular lenses implantation, allowing the ophthalmologist to take a personalized decision on the lens to be implanted based on the patient’s preferences.
"With several million people affected by these ocular conditions, the impact of SimVis is enormous. The availability of SimVis in the clinic reduces uncertainty both for the clinician and for the patient and decreases the number of patients dissatisfied or with undesired visual phenomena. In addition, from a scientific point of view, SimVis allows to design and validate new corrections that adapt to the needs of patients. Said Dr. Iñigo Jiménez Alfaro, Head of the Ophthalmology Service at Fundación Jiménez Díaz.
In 2015, Carlos Dorronsoro and Susana Marcos, co-inventors of the SimVis technology, promoted the creation of 2Eyes Vision and licensed from CSIC the patents protecting the technology. Since then, 2Eyes Vision, formed by an experienced and multidisciplinary team of engineers, ophthalmologists and optometrists, has proven the potential of the technology. SimVis will be commercially available in 2018 and was officially presented at ESCRS 2017, the largest exhibition of cataract and refractive surgery, that took place between the 7th and the 10th of October in Lisbon. Additionally, the core patent of the technology has been granted as the best patent in the XII edition of the MadrI+D awards.
According to Javier Ulecia from Bullnet Capital “2Eyes Vision is a company completely in line with our investment criteria: a team with proven experience in the technology world with patent-protected products, capable of creating new technologies and to develop an effective commercial strategy at a global level in sectors with growing demand”.
2Eyes Vision S.L
Entrevista con el Doctor Carlos Dorronsoro, miembro del Laboratorio de Óptica Visual y Biofotónica del Instituto de óptica del CSIC
La semana pasada nos hacíamos eco de la concesión del premio concedido por la Fundación Madri+d a la mejor patente, otorgado este año al Laboratorio de Óptica Visual y Biofotónica del Instituto de óptica del CSIC por la creación de un instrumento miniaturizado de visión simultánea. El invento supone una mejora significativa del proceso de probatura de la visión que pueden ofrecer las lentes bifocales. Hemos tenido la oportunidad de ponernos en contacto con uno de los tres investigadores que han participado en el desarrollo del invento, el Dr. Carlos Dorronsoro, que ha tenido la amabilidad de contestar a nuestras preguntas. Esperamos que la entrevista os resulte interesante. Continua leyendo aquí
El pasado 30 de mayo la Fundación para el Conocimiento madri+d convocó la duodécima edición de sus premios, concurso público mediante el que la Comunidad brinda a los mejores equipos de investigación de la región un merecido reconocimiento. Su trabajo se valora como importante fuente de riqueza, ya que supone el empleo de conocimientos técnico-científicos en el desarrollo de avances aplicables a la creación de productos y servicios mejorados, lo que redunda en la creación de empresas innovadoras. Click para más información
The main patent protecting the SimVis technology was awarded las week as the best patent by the XII Edition of the MadrI+D awards. The jury has valued the technology´s potential to positively influence the lives of millions of people by improving the prescription of intraocular and contact lenses for presbyopia and cataracts, conditions affecting more than 1.2B people worldwide.
MadrI+D press Release
CSIC press release
From left to right: Carlos Dorronsoro, Jose Ramon Alonso and Susana Marcos, inventors of the technology, pose with the latest prototype of SimVis.
2EyesVision presented this year at the European Society of Cataract and Refractive Surgery Exhibit the SimVis technology, where hundreds of delegates could experience multifocality with SimVis latest prototype. We would like to thank everyone that passed by our booth for all the feedback and great response on the technology. Without doubt SimVis will give a lot to talk about in the next years.
In 2015 2Eyes Vision licensed the SimVis technology to the Spanish National Research Center. SimVis will have a major clinical impact in the field of presbyopia corrections, as it will change the way these corrections are prescribed: it allows the patient to experience the real world through multifocal corrections before surgery.
Two years later, we are proud to announce that the technology will be officially presented at ESCRS 2017, which will take place in Lisbon between the 7th and the 10th of October. Enrique Gambra, CTO of 2Eyes Vision and Álvaro Sánchez-Lozano, business deveoper, will be showcasing the latest version of the device. Do not miss out and pass by booth P1147 for a demo.